tiprankstipranks
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY)
:DRREDDY
India Market
DRREDDY
Dr. Reddy's Laboratories Ltd.
RESEARCH TOOLSreports
Want to see IN:DRREDDY full AI Analyst Report?

Dr. Reddy's Laboratories Ltd. (DRREDDY) Earnings Dates, Call Summary & Reports

10 Followers

Earnings Data

Report Date
Jul 29, 2026
Before Open (Confirmed)
Period Ending
2027 (Q1)
Consensus EPS Forecast
9.6
Last Year’s EPS
17.02
Same Quarter Last Year
Analyst Consensus
Moderate Sell
Based on 2 Analysts Ratings

Earnings Call Summary

Q4 2026
Earnings Call Date:May 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
Mixed: the company reported its highest-ever annual revenues and demonstrated resilient base-business growth across geographies, secured important regulatory approvals (semaglutide in Canada, oral semaglutide and abatacept BLA acceptance) and maintained cash and dividend strength. However, Q4 profitability was materially affected by one-offs — notably a large lenalidomide shelf-stock adjustment (INR 453 crores), higher impairment and provisions, and significant margin compression and EBITDA decline. Management expects margins and R&D/run-rate improvements in FY'27 and has set clear pipeline and commercial milestones that could restore profitability, but near-term results remain impacted by the one-time items and some regulatory delays.
Company Guidance
Management guided that the underlying base business should sustain double‑digit growth and margins should recover, targeting gross margin above 50% in FY27 (Q4 adjusted gross 48%; FY26 adjusted gross 53.5%) and moving closer to an aspirational ~25% EBITDA margin over time (FY26 adjusted EBITDA ~INR 8,419 crores / 24.7%; Q4 adjusted EBITDA 19.5%). They expect SG&A in nominal terms to be roughly flat with FY26 (SG&A FY26 ~INR 10,435 crores, ~31% of adjusted revenue), R&D to be ~7–8% of revenues going forward (R&D FY26 ex‑one‑offs INR 2,385 crores; Q4 INR 541 crores ~6%), an effective tax rate of ~24–25% in FY27, and FY27 CapEx around INR 2,000 crores. On semaglutide management reiterated ~12 million pens/units across markets in FY27 (roughly 6–7m by end‑calendar 2026), a floor price assumption near $25–30/unit, an expected run‑rate of ~3–4m pens/quarter, and an approximate 50:50 split between direct sales and partner sales; abatacept IV BLA review is underway with a potential launch in early calendar 2027, biosimilars ambition of roughly $0.5–0.7bn annual sales by FY29, and the company entered FY27 with a net cash surplus of INR 3,271 crores (Mar 31, 2026).
Record Annual Revenue and Base Business Growth
Highest-ever annual revenues: adjusted FY'26 revenue INR 34,046 crores (USD 3.63 billion), up 4.6% YoY. Underlying base business delivered double-digit growth in Q4 and for the full year (excluding lenalidomide).
Quarterly and Annual Adjusted Revenue
Adjusted Q4 revenue (ex-SSA) was INR 7,969 crores (USD 849 million); Q4 decline of 6% YoY and 9% QoQ, while FY'26 adjusted revenue grew 4.6% YoY to INR 34,046 crores.
Improving Profitability Targets and Margins
Adjusted FY'26 EBITDA (incl. other income) INR 8,419 crores (USD 897 million) with an adjusted EBITDA margin ~24.7% for the year. Management target to drive margins above 50% gross and move toward aspirational ~25% EBITDA with product launches and cost initiatives.
Key Pipeline and Regulatory Progress
Semaglutide injection approval in Canada (first company), launched Obeda in India; oral semaglutide approved in India. U.S. FDA accepted BLA for IV abatacept biosimilar; denosumab expected to launch in Europe. These pipeline wins materially advance biosimilars & peptide franchise.
Geographic Growth and New Product Introductions
Emerging markets Q4 revenue INR 1,806 crores (+29% YoY) and FY +23% YoY. India Q4 revenue INR 1,566 crores (+20% YoY), FY INR 6,219 crores (+16% YoY). North America added 7 new products in Q4 (25 in FY). Company introduced 49 products in Q4 across markets (129 in FY).
Operational and Financial Strength
Free cash flow before acquisitions FY'26 INR 2,004 crores (USD 214 million); CapEx FY'26 INR 2,302 crores; net cash surplus INR 3,271 crores (USD 349 million) as of March 31, 2026. Board recommended dividend INR 8/share (800% of face value).
Cost Discipline and R&D Efficiency
Adjusted R&D spend Q4 INR 541 crores (down 26% YoY) and FY INR 2,385 crores (down 13% YoY). Management expects R&D run-rate ~7%–8% of revenue going forward reflecting completion of major abatacept development stages and productivity gains.
Sustainability and Corporate Recognition
Awarded EcoVadis Gold (score 80, top 5% globally), named among India Top 5 sustainable companies and ranked first in Indian health care & pharma for 2024–25; leadership category recognition for corporate governance for third consecutive year.

Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

IN:DRREDDY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 29, 2026
2027 (Q1)
9.60 / -
17.02―――
May 12, 2026
2026 (Q4)
11.06 / 5.80
19.11-69.65% (-13.31)――
Jan 21, 2026
2026 (Q3)
13.76 / 14.52
16.94-14.29% (-2.42)――
Oct 24, 2025
2026 (Q2)
16.99 / 17.25
15.0414.69% (+2.21)――
Jul 23, 2025
2026 (Q1)
18.38 / 17.02
16.6921.97% (+0.33)――
May 09, 2025
2025 (Q4)
18.18 / 19.11
15.6721.95% (+3.44)――
Jan 23, 2025
2025 (Q3)
17.91 / 16.94
16.5362.44% (+0.40)――
Nov 05, 2024
2025 (Q2)
17.33 / 15.04
17.756-15.30% (-2.72)――
Jul 27, 2024
2025 (Q1)
16.06 / 16.69
16.844-0.90% (-0.15)――
May 07, 2024
2024 (Q4)
14.70 / 15.67
11.52435.98% (+4.15)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

IN:DRREDDY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 12, 2026
₹1279.70₹1270.10-0.75%
Jan 21, 2026
₹1166.90₹1155.50-0.98%
Oct 24, 2025
₹1279.85₹1284.00+0.32%
Jul 23, 2025
₹1240.40₹1247.55+0.58%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) report earnings?
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).
    What is Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time?
    Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time is at Jul 29, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Dr. Reddy's Laboratories Ltd. stock?
          The P/E ratio of Dr. Reddy's Laboratories Ltd. is N/A.
            What is IN:DRREDDY EPS forecast?
            IN:DRREDDY EPS forecast for the fiscal quarter 2027 (Q1) is 9.6.